2010
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler
Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, Kloczynski T, Perry E, Seibyl JP, McKee S, Staley JK, Cosgrove KP. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. The International Journal Of Neuropsychopharmacology 2010, 14: 389-398. PMID: 21029513, PMCID: PMC3510008, DOI: 10.1017/s1461145710001227.Peer-Reviewed Original ResearchConceptsNicotine inhalerWithdrawal symptomsReceptor occupancyTobacco smokingLow nicotine cigarettesAdministration of nicotineHigh receptor occupancyDoses of nicotineNicotinic acetylcholine receptorsInhaler useTobacco smokersBaseline scanRegular cigarettesInhalerConstant infusionAcetylcholine receptorsSPECT studiesCigarettesSymptomsBeta 2Significant decreaseNicotineSignificant differencesSmokingNAChRs
2009
GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression
Esterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, Perry E, Tamagnan GD, Seibyl JP, Makuch R, Krishnan‐Sarin S, O'Malley S, Staley JK. GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse 2009, 63: 1089-1099. PMID: 19642218, PMCID: PMC2778224, DOI: 10.1002/syn.20688.Peer-Reviewed Original ResearchConceptsSpielberger State-Trait Anxiety IndexState-Trait Anxiety IndexDepressive symptomsSubsyndromal anxietyAnxiety symptomsPain toleranceReceptor availabilityAbstinent tobacco smokersSex-matched nonsmokersSingle photon emissionPain symptomsHealthy ageSmoking statusTobacco smokersSubsyndromal depressionAbstinent smokersVulnerable smokersCold pressor taskNonsmokersGamma-aminobutyricEpidemiology ScaleSmokersAcute abstinenceBrain areasSymptoms
2005
Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence
Perry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.Peer-Reviewed Original ResearchCocaine abusePsychiatric symptomsCocaine cravingCatecholamine reuptake inhibitorCurrent antipsychotic medicationsCocaine consumptionPlacebo groupAntipsychotic pharmacotherapyReuptake inhibitorsAntipsychotic medicationAntipsychotic treatmentComorbid schizophreniaSchizoaffective patientsSubstance abuse issuesSchizophrenic patientsPatientsSchizoaffective disorderSchizophrenia patientsNatural historyMazindolPilot studyGroup therapySchizophreniaSymptomsAbuse issues
2004
Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
D'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.Peer-Reviewed Original ResearchReceptor dysfunctionCannabinoid compoundsCannabis consumptionPathophysiology of psychosisPathophysiology of schizophreniaRecent pharmacological studiesPrincipal psychoactive constituentEffects of exposurePostmortem studiesNormal controlsPsychotic symptomsPsychotic disordersPharmacological studiesPsychosisPsychoactive constituentPathophysiologyΔ9-tetrahydrocannabinolSchizophreniaCannabisDysfunctionAssociationPossible mechanismPatientsSymptomsPharmacological